ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Refractory Thrombotic Thrombocytopenic Purpura – A Case Report

A. Aribandi1, C. Ranjith1, S. Sushma2, T. Surapaneni2

1American Oncology Institute, Hyderabad, India, 2Fernandez Foundation, Hyderabad, India

Abstract Number: PO161

Meeting: ISTH 2021 Congress

Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies » ADAMTS13 and TTP

Background: Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, fever, Neurologic abnormalities, and acute renal insufficiency.

Aims: To present the diagnosis and management of a case of refractory thrombotic thrombocytopenic purpura.

Methods: Hematological and biochemical  studies were done .ADAMS 13 activity  & antibodies were measured in our case to detect TTP.

Results: 27 year old lady, G3A2, at 21Weeks 6 days, was diagnosed to have Intrauterine fetal demise, so termination of pregnancy was done and she was advised LMWH for 6 weeks post-delivery. On PND 3 she presented with C/O giddiness and burning micturition.On evaluation her CBC was 6gm/dl and platelets were 20000/mm3. Peripheral smear showed schistocytes with thrombocytopenia. PT & APTT were normal. Empirical diagnosis of TTP was made and she was started on steroids and plasmapheresis. ADAMS 13 activity was <3 and ADAMTS inhibitor was >32. She received in total, 4 doses of Rituximab (weekly) & 2 doses of weekly iv vincristine (2mg) along with 29 cycles of plasmapheresis and was discharged when her platelet count was 1,66,000/mm3. She was again readmitted after 10 days with platelet count 18,000/mm3. Rpt ADAMTS activity was -<3 (n-68-163), ADAMTS inhibitor was >1.5 (n-<0.4). She received 5 cycles of plasmapheresis along with cyclosporine, which was added as a last resort. She was discharged on oral steroids and oral cyclosporin 100mg bd .Platelet count at the time of discharge was 2,05,000/mm3. She continues to be in remission post cyclosporine and is in follow up till now.      

Conclusions: We present an unusual case of  Thrombotic thrombocytopenic purpura, which was refactory to the usual treatments, i.e plasmapheresis ,rituximab and vincristine. In our case cyclosporine was effective along with plasmapheresis, so cyclosporine can be used in case of refractory TTP for remission.

To cite this abstract in AMA style:

Aribandi A, Ranjith C, Sushma S, Surapaneni T. Refractory Thrombotic Thrombocytopenic Purpura – A Case Report [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/refractory-thrombotic-thrombocytopenic-purpura-a-case-report/. Accessed May 20, 2022.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/refractory-thrombotic-thrombocytopenic-purpura-a-case-report/

Simple Search

Supported By:

Bristol Myers Squibb and Pfizer

ISTH 2021 Congress site

Visit the official web site for the ISTH 2021 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley